FDA 21 CFR Part 111 — cGMP Requirements for Dietary Supplements
21 CFR Part 111 establishes current Good Manufacturing Practice (cGMP) requirements for dietary supplement manufacturers, packagers, labelers, and holders. Every supplement brand that manufactures, packages, labels, or holds a product is subject to Part 111 — and cGMP violations are one of the most common findings in FDA facility inspections.
21 CFR Part 111 is the FDA's current Good Manufacturing Practice regulation for dietary supplements. It governs the methods, facilities, and controls used in the manufacturing, packaging, labeling, and holding of dietary supplements to ensure their quality, identity, purity, strength, and composition.
Unlike pharmaceutical GMP, Part 111 does not require pre-market approval — but it does require that every supplement company maintain systems, records, and testing protocols that demonstrate ongoing compliance. FDA inspects against Part 111 requirements during routine facility inspections, and warning letters citing cGMP violations frequently accompany safety-related enforcement actions.
Who Must Comply with 21 CFR Part 111
Every domestic and foreign establishment that manufactures, packages, labels, or holds dietary supplements for US distribution must comply with 21 CFR Part 111. This includes:
Finished dietary supplement manufacturers
Contract manufacturers producing under a brand's specifications
Repackers and relabelers
Warehouses and distribution facilities that hold supplements
Foreign manufacturers exporting to the US
Brands that contract out manufacturing are still responsible for ensuring their contract manufacturers are cGMP-compliant.
Core cGMP Requirements
Written Procedures (SOPs)
21 CFR 111.10 requires that every manufacturing and quality control operation be governed by written procedures. These standard operating procedures (SOPs) must be followed in practice — not just documented. FDA inspectors look for evidence that SOPs are actually used, reviewed, and updated.
Personnel Qualifications and Training
Under 21 CFR 111.12–111.14, all personnel involved in manufacturing must be qualified by education, training, or experience for their specific roles. Training records must be maintained for FDA review.
Physical Plant and Equipment
21 CFR 111.15–111.30 covers facility and equipment requirements: adequate space and sanitary conditions, equipment that is properly designed and maintained, and cleaning procedures that prevent contamination and cross-contamination.
Component and Container Controls
21 CFR 111.70–111.80 requires that all incoming ingredients (components) and packaging materials be received, identified, tested, and approved before use. Identity testing of each component lot is required — relying solely on a supplier's certificate of analysis is not sufficient to meet the identity testing requirement under Part 111.
Manufacturing Operations
21 CFR 111.205–111.260 governs the manufacturing process itself — batch production records, in-process controls, equipment cleaning records, and procedures to prevent errors, contamination, and mix-ups.
Quality Control
21 CFR 111.65–111.68 requires that every supplement company establish and operate a quality control system. A qualified quality control (QC) person must oversee operations and have authority to reject any batch that does not meet specifications.
Laboratory Operations and Finished Product Testing
21 CFR 111.310–111.330 requires testing of finished batches for identity, purity, strength, and composition. Brands must establish product specifications and verify that each batch meets those specifications before release.
Reserve Samples
21 CFR 111.83 requires that reserve samples of each lot of finished product be retained and stored under conditions consistent with product labeling, for a period of at least one year past the product's expiration date.
Recordkeeping
21 CFR 111.95–111.100 requires that all cGMP-related records be maintained for at least one year past the shelf life of the product, or two years past the date of manufacture if the product has no expiration date. Records must be available for FDA inspection.
Consumer Complaint Handling
Under 21 CFR 111.553–111.570, supplement companies must have a written procedure for reviewing and investigating consumer complaints. Every complaint must be reviewed by a qualified person, and complaints involving potential cGMP issues must be documented in a record that includes the findings and follow-up actions taken.
Common cGMP Violations Cited in FDA Warning Letters
Based on FDA inspection and enforcement patterns, the most frequently cited Part 111 violations include:
Failure to conduct identity testing on incoming ingredients — relying on a COA without in-house testing
Inadequate batch production records — missing signatures, incomplete lot tracking
Failure to establish finished product specifications — no defined criteria for what constitutes a passing batch
Failure to investigate consumer complaints — no written procedure or documentation of investigations
Inadequate facility sanitation procedures — no written cleaning protocols or cleaning records
Failure to qualify laboratory personnel — testing performed without documented qualifications
Missing or deficient reserve samples — samples not retained or stored incorrectly
How Truli Helps with 21 CFR Part 111 Compliance
Truli supports supplement brands in understanding their cGMP obligations and identifying compliance gaps:
cGMP gap analysis: Truli maps your current manufacturing and quality documentation against Part 111 requirements to identify gaps before an FDA inspection
Supplier audit support: Truli helps brands evaluate contract manufacturer cGMP documentation and identify questions to ask CMOs about identity testing, batch records, and QC systems
Warning letter intelligence: Truli tracks FDA inspection findings and warning letters to surface the cGMP violation patterns most relevant to your product category
Related Regulations
21 CFR Part 101 — Food labeling requirements including Supplement Facts panels
DSHEA — The Dietary Supplement Health and Education Act
NDI Notification Requirements — Pre-market notification for new dietary ingredients
Frequently Asked Questions
Does Part 111 apply to small supplement brands?
Yes. There is no small business exemption from 21 CFR Part 111 for dietary supplements. Every manufacturer, packager, labeler, or holder — regardless of size — must comply.
Does my contract manufacturer handle cGMP compliance?
Your contract manufacturer is responsible for their own cGMP compliance, but your brand is responsible for ensuring the products you sell meet Part 111 requirements. If your CMO has a cGMP violation, your products may still be subject to FDA action.
How often does FDA inspect supplement manufacturers?
FDA does not inspect supplement facilities on a fixed schedule. Inspections can be triggered by consumer complaints, adverse event reports, import alerts, or routine surveillance. High-risk categories (weight loss, sports nutrition, sexual enhancement) tend to receive more frequent inspections.
A note from Truli: Truli is not a law firm, and this article does not constitute or contain legal advice or create an attorney-client relationship. When determining your obligations and compliance with respect to relevant laws and regulations, you should consult a licensed attorney.
Last updated: April 2026. Truli monitors FDA inspection activity and cGMP guidance updates. Book a demo to see how.
About
Truli is an AI compliance platform for food, beverage, and supplement brands. Automate FDA/FTC label reviews, claims validation, and post-market monitoring — 10x faster.
Platform
See Truli in action
If regulatory delays are consuming months and thousands in fees, see how Truli delivers fast and continuous compliance coverage at a fraction of the cost.
